Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. To be honest, very good progress has been ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and aggressive ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We already know CAR T, cellular therapy, ...

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches. If you have the appropriate software installed, you can download article citation data to the citation manager ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Mantle cell lymphoma (MCL) remains one of the more challenging B-cell non-Hodgkin lymphomas, distinguished by its aggressive clinical course and complex molecular signature. Recent investigations have ...

December 19, 2007 (Atlanta) — Results obtained with an intensive immunotherapy regimen in mantle-cell lymphoma are so good that they suggest that a cure is in sight, said Christian Geisler, MD, PhD, ...

Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...

Authors Compare Bridging Therapy Strategies Prior to Brexu-Cel in MCL Meta-analysis across B-cell lymphomas shows zanubrutinib (Brukinsa) delivers higher ORR/CR than acalabrutinib (Calquence) or ...